BioCryst Pharmaceuticals
BCRX
116 hedge funds and large institutions have $443M invested in BioCryst Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 23 closing their positions.
96% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 23
57% more call options, than puts
Call options by funds: $907K | Put options by funds: $577K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
6.96% more ownership
Funds ownership: 84.81% → 91.78% (+7%)
1% more capital invested
Capital invested by funds: $439M → $443M (+$4.9M)
3% less funds holding
Funds holding: 120 → 116 (-4)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.1M |
| 2 |
DM
Deerfield Management
New York
|
+$10.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$10.7M |
| 4 |
BlackRock
New York
|
+$4.81M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$6.96M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.76M |
| 3 |
VMI
VHCP Management II
New York
|
-$3.31M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.68M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$146K | -27,923 | Closed |
|
127
SG Americas Securities
New York
| – | -$141K | -26,990 | Closed |
|
128
Los Angeles Capital Management
Los Angeles,
California
| – | -$132K | -25,170 | Closed |
|
|
FRM
129
Fox Run Management
Greenwich,
Connecticut
| – | -$123K | -23,400 | Closed |
|
|
NIT
130
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$116K | -22,200 | Closed |
|
|
GCP
131
GSA Capital Partners
London,
United Kingdom
| – | -$69K | -13,086 | Closed |
|
132
Wolverine Trading
Chicago,
Illinois
| – | -$55K | -10,480 | Closed |
|
|
PP
133
Paloma Partners
Greenwich,
Connecticut
| – | -$54K | -10,328 | Closed |
|
|
CG
134
Cutler Group
San Francisco,
California
| – | -$40.4K | -8,332 | -99% |
|
|
FPF
135
FNY Partners Fund
New York
| – | -$20K | -4,000 | Closed |
|
|
IA
136
IFP Advisors
Tampa,
Florida
| – | -$5K | -1,000 | Closed |
|
|
AIM
137
Advantage Investment Management
Cedar Rapids,
Iowa
| – | -$3K | -560 | Closed |
|
|
WAS
138
Winch Advisory Services
Appleton,
Wisconsin
| – | -$1K | -200 | Closed |
|
BCRX Hedge Fund Activity: Q4 2017 in Review
116 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2017, worth a combined $443M — up 1.1% from $439M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BCRX and 19 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 45 added.
The largest buyer was Great Point Partners, adding an estimated $15.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $6.96M.
- 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2017, down from 120 in Q3 2017.
- Funds reported $443M of BioCryst Pharmaceuticals stock for Q4 2017, up 1.1% quarter-over-quarter.
- 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2017 and 23 closed out, a net change of -4 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2017 was Great Point Partners, an estimated $15.1M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2017 was Avoro Capital Advisors, an estimated $6.96M sold.
Based on aggregated 13F filings for Q4 2017.